Consumer comparison
Oura Ring 4 vs RingConn (Gen 2 / Gen 3) vs Whoop (5.0 / MG) in 2026
Comparing 3 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | Oura Ring 4 | RingConn (Gen 2 / Gen 3) | Whoop (5.0 / MG) |
|---|---|---|---|
| Manufacturer | Oura | RingConn | Whoop |
| Form factor | biometric | biometric | biometric |
| Maturity | commercial | commercial | commercial |
| Availability | shipping-nowshipping | shipping-nowshipping | shipping-nowshipping |
| Price | $349-$499 (actual sale price) | $279 (actual sale price) | Not announced |
| Capability claims | — | — | — |
| Brain | — | — | — |
| Verified deployments | 0 | 0 | 0 |
| Privacy practices | — | — | — |
| Sources on file | 7 | 6 | 7 |
Editorial summaries
Oura Ring 4
The Oura Ring 4 (Gen 4, late 2024, from Oura, founded 2013 in Oulu, Finland) is a titanium biometric smart ring and the study-first archetype of the biometric cohort. Its 'Smart Sensing' recessed sensors (PPG heart rate and HRV, red and infrared blood-oxygen, multi-point skin temperature, accelerometer) feed 50-plus metrics: sleep staging and Sleep Score, Readiness, Activity, stress, cycle tracking, a VO2 Max estimate, and an LLM 'Oura Advisor'. It is sold as a purchase (from about $349) plus a required Oura Membership ($5.99/month); the AI augments genuine biometric sensing rather than being the product. DEPLOY records commercial maturity and a reported $11 billion valuation (October 2025). The verified-vs-claimed throughline: Oura is positioned as general wellness and is not FDA-cleared for diagnostics, and it ran a blood-pressure study in December 2025 before marketing blood pressure, the study-first counterpoint to Whoop's market-first BP Insights. Oura is also the patent-holder in the smart-ring litigation (RingConn settled; Ultrahuman was ITC import-banned via the '178 patent).
RingConn (Gen 2 / Gen 3)
RingConn (the Gen 2 at about $279, plus the Gen 2 Air and a Gen 3 arriving late May 2026; from RingConn, Shenzhen) is the subscription-free archetype of the biometric ring sub-cohort: all standard features are free for life, the core positioning against Oura's required membership and Whoop's subscription-only model. Its sensors (PPG, skin temperature, SpO2, accelerometer) drive sleep, heart rate and HRV, and a deep-learning sleep-apnea / AHI screening feature, with 10-to-12-day battery (the charging case extends to about 150 days). The verified-vs-claimed throughline: the sleep-apnea / AHI feature is a company-claimed screening capability (RingConn cites about 90.7% accuracy) that is NOT FDA-cleared. RingConn's own materials say it is 'actively pursuing clearance' and 'not intended to diagnose'; DEPLOY records the AHI claim as claimed, not cleared, the direct counterpoint to the genuinely-cleared Happy Ring in the same form factor. On the patent front, RingConn settled and licensed cleanly in the smart-ring ITC litigation; it was not import-banned, unlike Ultrahuman. Price is $279, subscription-free.
Whoop (5.0 / MG)
Whoop (the 5.0 and the 'Medical Grade' MG, both launched May 8, 2025, from Whoop, founded 2012 in Boston by Will Ahmed) is a screen-free biometric wrist band and the subscription-only archetype of the biometric cohort: there is no standalone hardware sale. Access is a membership, Whoop One at $199/year, Peak at $239/year, and Life at $359/year (which includes the MG hardware), with the band provided inside the subscription. Its PPG, skin-temperature, SpO2, and respiratory sensors feed Strain, Recovery, and Sleep Coach analytics and an LLM 'Whoop Coach'; the MG adds ECG, Blood Pressure Insights, and a Healthspan / 'Whoop Age' feature. DEPLOY records commercial maturity and a reported $10.1 billion valuation (March 2026). Whoop is the strongest verified-vs-claimed cautionary exemplar in the cohort: its ECG is FDA-cleared (2025), but it marketed Blood Pressure Insights without clearance, drew an FDA Warning Letter on July 14, 2025, refused to remove the feature, and as of May 2026 the matter is unresolved with a class action filed, the market-first contrast to Oura's study-first posture.
Machine-readable: this page as markdown.